SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Böttcher Malin)
 

Sökning: WFRF:(Böttcher Malin) > Allergic disease in...

Allergic disease in infants up to 2 yr of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation inpregnancy and lactation

Furuhjelm, Catrin (författare)
Östergötlands Läns Landsting,Linköpings universitet,Pediatrik,Hälsouniversitetet,Barn- och ungdomskliniken i Linköping
Warstedt, Kristina (författare)
Linköpings universitet,Pediatrik,Hälsouniversitetet
Fagerås Böttcher, Malin (författare)
Linköpings universitet,Pediatrik,Hälsouniversitetet
visa fler...
Fälth-Magnusson, Karin (författare)
Östergötlands Läns Landsting,Linköpings universitet,Pediatrik,Hälsouniversitetet,Barn- och ungdomskliniken i Linköping
Larsson, Johanna (författare)
Pediatric Clinic, Ryhov Hospital, Jönköping, Sweden
Fredriksson, Mats (författare)
Linköpings universitet,Yrkes- och miljömedicin,Hälsouniversitetet
Duchén, Karel (författare)
Östergötlands Läns Landsting,Linköpings universitet,Pediatrik,Hälsouniversitetet,Barn- och ungdomskliniken i Linköping
visa färre...
 (creator_code:org_t)
2011-02-20
2011
Engelska.
Ingår i: Pediatric Allergy and Immunology. - : John Wiley & Sons A/S. - 0905-6157 .- 1399-3038. ; 22:5, s. 505-514
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • We have previously reported a protective effect of maternal omega-3 long-chain polyunsaturated fatty acids (x-3 LCPUFA) supplementation in pregnancy and lactation on IgE-associated eczema and food allergy in the infant during the first year of life. Here we investigate whether the effects of the LCPUFA supplementation on IgE-associated diseases last up to 2 yr of age and assess the relationship between plasma proportions of x-3 PUFAs and the frequency and severity of infant allergic disease. 145 pregnant women, at risk of having an allergic infant, were randomized to daily supplementation with 1.6 g eicosapentaenoic acid (EPA) and 1.1 g docosahexaenoic acid (DHA) or placebo starting in the 25th gestational week and continuing through 3.5 months of breastfeeding. Clinical examinations, skin prick tests and analysis of maternal and infant plasma phospholipid fatty acids and infant specific IgE were performed. No difference in the prevalence of allergic symptoms was found between the intervention groups. Thecumulative incidence of IgE-associated disease was lower in the x-3-supplemented group (6/54, 13%) compared with the placebo group (19/62, 30%, p = 0.01). Higher maternal and infant proportions of DHA and EPA were associated with lower prevalence of IgE associated disease (p = 0.01–0.05) in a dose-dependent manner. Higher maternal and infant proportions of DHA and EPA were found if the infants presented none, when compared with multiple allergic symptoms, (p < 0.05) regardless of sensitization. In summary, the x-3 supplementation offered no obvious preventive effect on the prevalence of clinical symptoms of allergic disease, but the decrease in cumulative incidence of IgE-associated disease seen during the first year still remained until 2 yr of age. Furthermore, high proportions of DHA and EPA in maternal and infant plasma phospholipids were associated with less IgE-associated disease and a reduced severity of the allergic phenotype.

Nyckelord

allergy; eczema; fatty acids; pregnancy; lactation; dietary supplements; infant
MEDICINE
MEDICIN

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy